[Event Report] FY2023 AMR Alliance Japan Planning Meeting (February 2, 2023)
date : 3/9/2023
Tags: AMR
AMR Alliance Japan (Secretariat: Health and Global Policy Institute) held a meeting to discuss its FY2023 plans among Alliance members.
AMR Alliance Japan, as an independent platform for multisector discussion with the mission of contributing to the improvement of public health by promoting measures on AMR, will continue to work with Alliance members and partner organizations to deepen policy debate around AMR.
■Overview
Date and time: Thursday, February 2, 2023
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Discussion
Participants (Titles omitted; in no particular order)
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Hiroshi Itoh (Internal Medicine, Medical Affairs, Pfizer Japan Inc.)
Rie Ueno (BioMérieux Japan Ltd, Director Medical Affairs)
Kazunobu Ouchi (President, Japanese Society for Pediatric Infectious Diseases / Specially Appointed Professor, Department of Medical Welfare for Children, Faculty of Health and Welfare, Kawasaki University of Medical Welfare / Specially Appointed Manager, Kawasaki Medical School General Medical Center / Professor emeritus, Kawasaki Medical School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Katsunori Kanazawa (Officer Infectious Diseases, Medical Information, Sumitomo Pharma Co., Ltd.)
Satoshi Kamayachi (Executive Board Member, Japan Medical Association)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Hayato Shishido (Manager, Business Development Department, Research & Development Division, NISSUI PHARMACEUTICAL CO., LTD)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Mitsuru Sugawara (President, Japanese Society of Therapeutic Drug Monitoring / Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Yoshisaburo Takahashi (General Manager, Vaccine/Infections Dept., Meiji Seika Pharma Co., Ltd.)
Hiroshi Taki (Manager, Policy & Public Affairs, Pfizer Japan Inc.)
Kazuhiro Tateda (Chairman, the Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, AMR Incentives and Advocacy TF, Japan Pharmaceutical Manufacturers Association)
Mitsuaki Nagasawa (Vice-president, Japanese Association of Medical Technologists)
Testuya Matsumoto (President, Japanese Society of Chemotherapy / President, Japanese society for clinical microbiology / Chief Professor, Department of Infectious Diseases, International University of Health and Welfare Graduate School of Medicine)
Megumi Maruyama (Global Health Officer, Sumitomo Pharma Co., Ltd.)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akira Yuasa (Senior Manager, HTA/HEOR, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control)
Hiroshi Yotsuyanagi (President, Japanese Association for Infectious Diseases / Director, IMUST Hospital, Institute of Medical Science, University of Tokyo)
Moderator:
Yui Kohno (Manager, Health and Global Policy Institute)
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Policy Recommendations] The Women’s Health Promotion Project “Policy proposal for Promotion of Menopausal Women’s Health as a Social Issue to be Considered by Industry, Government, Academia and the Private Sector” (July 31, 2024)
- [Reserch Report] Antimicrobial Resistance (AMR) Measures in Sweden (November 21, 2024)
Featured Posts
-
2024-11-25
[Registration Open] (Webinar) The 130th HGPI Seminar “Marking a Decade of the Act on Medical Care for Patients With Intractable Diseases: Connecting Intractable Diseases and Society From the Perspective of a Media Professional and Family Member” (January 28, 2025)
-
2024-11-29
[Registration Open] (Webinar) The 129th HGPI Seminar “The Connection Between Planetary Environment and Human Health as Seen Through the JECS and Future Expectations” (December 23, 2024)
-
2024-12-09
[Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
-
2024-12-12
[HGPI Policy Column] (No. 51) From the Planetary Health Project “Part 11: Efforts Toward Achieving Carbon Neutrality in Japan’s Pharmaceutical Industry”
-
2024-12-18
[Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)